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based on a randomized trial directly comparing bicalutamide 
and ﬂutamide. Costs and quality of life effects related to therapy
were based on published sources. Cost-effectiveness was calcu-
lated for 60 and 120 months from start of therapy. RESULTS:
The incremental cost per quality adjusted life year (QALY)
gained for bicalutamide vs. ﬂutamide was $22,000 and $16,000
per QALY at ﬁve and ten years, respectively. If quality adjust-
ment was not included, the incremental cost-effectiveness ratio
(ICER) for CAB with bicalutamide over CAB with ﬂutamide was
even more favorable ($20,000/LY gained at ﬁve years). These
ICER estimates are well within the commonly accepted cost-
effectiveness threshold. One way sensitivity analysis demon-
strated that the cost-effectiveness estimates were most sensitive
to drug costs and survival (baseline survival was not signiﬁcantly
different between therapies). Multi-way uncertainty analysis
revealed that the median value of the ICER at ﬁve years was
$13,637/QALY when all the parameters were varied over a clin-
ically reasonable range. CONCLUSIONS: Bicalutamide is cost-
effective compared with ﬂutamide when used for androgen
blockade as part of combined androgen blockade for men with
advanced prostate cancer.
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RESOURCE UTILIZATION AMONG PROSTATE CANCER
PATIENTS WITH BONE PAIN
Kurth H1, McKiernan J2,Thomas SK3, Bentkover JD1
1Innovative Health Solutions, Brookline, MA, USA; 2Columbia
Presbyterian, New York, NY, USA; 3Novartis Pharmaceuticals Corp,
East Hanover, NJ, USA
OBJECTIVES: Bone metastases occur in up to 80% of advanced
prostate cancer patients, and could result in painful and debili-
tating skeletal complications. The objective of this study was to
evaluate resource utilization in advanced prostate cancer patients
with versus without bone pain. METHODS: A multi-center ret-
rospective chart review combined with prospective quality of 
life and pain assessment study was initiated to collect data 
from approximately 375 patients from 73 US community
urology practices. Patients were categorized as either with or
without bone pain. Interim analysis compared resource utiliza-
tion (hospitalizations, physicians visits) between the two groups,
using t-tests and Chi-square tests (p < 0.05) to assess differences.
RESULTS: Of 277 patients recruited to date, mean age was 76
years, and majority (74%) were Caucasian. About 39% (N =
109) had bone pain and the remaining 61% did not. Patients
with bone pain were signiﬁcantly younger than those without
(75 vs. 77 years) and more likely to have bone metastases (62%
vs. 40%). However, the groups did not differ signiﬁcantly in eth-
nicity, education, or comorbid conditions. Patients with bone
pain were over twice as likely to have been hospitalized in the
past year (28% vs. 13%) than those without and averaged 1.3
hospitalizations per patient and 4.2 days per stay. While outpa-
tient visit rates were similar, patients with bone pain were less
likely to make routine physician visits (42% versus 61%),
instead seeking treatment for non-routine reasons (e.g. LH-RH
agonist administration, initial/post-op consults, procedures/
surgery). Patients with bone pain were more likely to visit for
SRE (8% vs. 3%) and to receive a referral to oncology/urology
(6% vs. 3%) at physician visits. CONCLUSIONS: Patients with
bone pain have increased health resource consumption, particu-
larly hospitalizations, than patients without bone pain, which
may result in substantial economic burden.
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OBJECTIVE: Sepsis is a systemic inﬂammatory syndrome in
response to infection. Sepsis is considered severe when associated
with organ dysfunction, hypoperfusion, or hypotension. Severe
sepsis is considered the most common cause of death in non-
coronary critical care units. The impact of severe sepsis on the
oncology population has not been fully delineated. The objective
of this observational study is to describe the clinical outcomes
and direct medical costs of treating severe sepsis in the oncology
population at a comprehensive cancer center. METHODS: A
convenience sample of 20 intensive care unit patients diagnosed
with severe sepsis was followed prospectively during their severe
septic episode until death or hospital discharge. Clinical infor-
mation was obtained from the patient medical record. Resource
utilization and costs were retrieved from the institution’s ﬁnan-
cial database. RESULTS: The sample was 60% male with a mean
age of 63 years (27–82). The medical/surgical mix of patients
was 50/50. Sixty percent of patients had solid tumors and 40%
had hematological malignancies. Four patients were neutropenic
on ICU admission. Eighty percent of patients had an APACHE
II score ≥25 on admission to the ICU. The majority of patients
required vasopressor support (95%) and mechanical ventilation
(85%). Eight patients (40%) required dialysis and seven patients
(35%) received drotrecogin alfa. The lung was the most common
presumed infection source. The mean length of stay in the ICU
was 16 days (1–41). Survivors constituted 25% of the group.
The top cost drivers for physician services included: 1) intensive
care unit; 2) nephrology; and 3) radiology and for hospital care
included: 1) room and board; 2) pharmacy; and 3) respiratory
care. A detailed cost analysis is ongoing. CONCLUSION: The
clinical outcomes of oncology patients who develop severe sepsis
are poor despite intensive therapeutic intervention and resultant
high resource utilization and costs.
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OBJECTIVE: To determine breast cancer knowledge, screening
behavior, perceived risk, and willingness to consume chemopre-
ventive agent and their interrelationships in West Virginia 
Medicaid Program (WVMP) women enrollees. METHODS: A
survey of randomly selected women >40 years of age who were
enrollees of WVMP was conducted. The questionnaire collected
information on following components: utilization of breast
cancer preventive strategies, perceived and actual (as calculated
by Gail model) risk of breast cancer, breast cancer knowledge,
and willingness to consume chemopreventive agents. RESULTS:
A total of 606 responses were obtained from a reachable sample
size of 1502, yielding a response rate of 40.4%. Non–response
bias assessment indicated minimal potential for non-response
bias. Only 50.7% of respondents were compliant with the 
American Cancer Society screening guidelines. Almost none of
the respondent (96.7%) had ever taken chemopreventive tamox-
ifen. A large proportion of respondents were not sure about their
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breast cancer risk, while 11.6% and 14.3% of respondents
believed that they were at higher 5-year and lifetime risk of
breast cancer as compared to an average woman, respectively. A
low but signiﬁcant correlation (0.167, p = 0.045) was found
between respondents’ actual risk and perceived risk of breast
cancer. A large proportion of women (42.6%) were not sure
whether or not they would consume chemopreventive tamoxifen
for breast cancer if advised by their doctor. Only 16.7% women
expressed willingness to consume tamoxifen. No relationship
was found between women’s perceived and actual risk of breast
cancer and their mammography screening behavior or willing-
ness to consume chemopreventive tamoxifen. CONCLUSIONS:
Actual and perceived risk of breast cancer does not seem to be
associated with their screening behavior or willingness to
consume chemopreventive tamoxifen in this population. 
Relatively few women in this population may opt to consume
chemopreventive tamoxifen for reducing their risk of breast
cancer.
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OBJECTIVES: To investigate opioid use in a large sample of
hospice patients and examine differences in opioid use between
cancer and non-cancer patients. METHODS: This project was
conducted with excelleRx, a large hospice pharmacy provider
which contracts with 15% of hospices throughout the US.
Patients included were age 65 or older admitted to hospice
between June 1, 2003 and December 31, 2003. Pharmacy data
through June 30, 2004 was analyzed. Average daily opioid equiv-
alent (ADOE) use was calculated for each patient by converting
total opioid dispensed to morphine equivalents. Associations
between demographic variables and clinical characteristics with
opioid use were examined. Analysis of variance (ANOVA) was
conducted to examine differences in opioid use between cancer
and non-cancer patients. RESULTS: The sample consisted of
43,537 patients representing 4 diagnostic categories: cancer
(46%); heart diagnoses (13%); lung diagnoses excluding lung
cancer (7%); and other (33%). Half (n = 21,767 patients) were
dispensed 1 or more opioids during their hospice stay. For these
patients, the ADOE ranged from 0.03 to 15,305 (mean = 47.0;
SD = 140.0). There was a signiﬁcant inverse correlation (p <
0.0001) between opioid use and age, and male patients were dis-
pensed more opioids (mean = 50.2 ADOE) than females (mean
= 44.1 ADOE, p < 0.05). There were no differences in opioid
use by race, hospice region, or hospice size. ANOVA testing
revealed that opioid use among patients with a hospice diagno-
sis of cancer differed from those without cancer (ADOE = 54.3
cancer vs. 35.0 non-cancer; p < 0.0001), and mean length of
hospice care was shorter for cancer vs. non-cancer patients (43.4
days and 55.2 days, respectively; p < 0.0001). CONCLUSIONS:
Few studies have investigated opioid use in a national hospice
population, in particular, the differences between cancer and
non-cancer patients. Signiﬁcant differences in opioid use were
noted, suggesting the need for further research on how to best
deliver hospice services for this fragile population.
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Prostate cancer is the most common cancer affecting American
men and the second leading cause of cancer deaths in the US.
African-American men have the highest prostate cancer inci-
dence and mortality rates in the world. OBJECTIVE: The
purpose was to investigate differences across racial groups in 
the disease state and treatment of men hospitalized for prostate
cancer. METHODS: Data Source—Florida Agency for Health
Care Administration (AHCA) hospital discharge data for 2002.
Each record represents a patient discharge and includes patient
demographics, diagnoses, procedures and charges for the stay.
Study population includes all patients under 80 years old with 
a primary diagnosis of prostate cancer hospitalized in Florida
during 2002. Analysis: SPSS was used to compare procedures,
co-morbidities, and patient outcomes of discharge status, length-
of-stay and total charges. Chi-Square tests and ANOVA were
used to detect signiﬁcant differences across racial groups.
RESULTS: A total of 5444 men were included in the analysis.
The average age was 64.5 years, with 73% of the patients 
Caucasian, 12% African-American, 11% Hispanic and 4%
other races. Average length of stay was 3.3 days, costing about
$23,000 per stay. Medicare was the primary payer for over 47%
of the hospitalizations. Prostatectomy was performed on 81.5%
of the patients with no signiﬁcant differences across racial
groups. Hypertension was reported in 41.5% of the patients,
occurring signiﬁcantly more in African American patients. On
average, African Americans had signiﬁcantly higher hospital
charges and length of stay, yet were signiﬁcantly younger than
Caucasians. Finally, African Americans were more likely to have
a discharge status of death than any other racial group. CON-
CLUSIONS: African American men hospitalized for prostate
cancer have very different experiences than men of other racial
groups. Further research is necessary to determine why this dis-
parity occurs and how it might be attenuated.
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OBJECTIVE: Colorectal Cancer (CRC), when detected early,
can be treated, reducing morbidity and mortality. In 1997, the
American Cancer Society issued major revisions for CRC screen-
ing guidelines to include new research ﬁndings and improve-
ments in testing accuracy. Research suggests that physicians do
not always follow CRC screening guidelines; lack of knowledge
about appropriate guidelines or guideline changes is often cited
as a barrier. The aim of this systematic review was to examine
studies measuring physician CRC screening knowledge and
related practice patterns. METHODS: A tiered systematic search
(1997–2004) was conducted for studies, irrespective of design,
which were published in peer-reviewed journals through
MEDLINE, Academic Search Elite, CancerLit, CINAHL, and
PsycINFO databases. Tier 1 search combined keywords “knowl-
edge” and “physicians” with “colorectal cancer screening”
which identiﬁed 48 studies. Tier 2 search combined keywords
“practice patterns” and “physicians” with “colorectal cancer
screening” which identiﬁed 52 studies. Tier 3 was a review of
papers identiﬁed in Tiers 1 and 2. Ten studies meeting the
“knowledge” and “practice patterns” inclusion criteria were
retained. RESULTS: Studies reported that a signiﬁcant percent-
age of physicians were performing Fecal Occult Blood Test on
stool samples obtained from Digital Rectal Examination, a
method that often produces false results. Roughly half of physi-
cians were reported to be performing screening tests without
